Immuneering Corporation (NASDAQ:IMRX) CEO Benjamin J. Zeskind Buys 7,015 Shares

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) CEO Benjamin J. Zeskind bought 7,015 shares of the stock in a transaction on Wednesday, July 2nd. The shares were acquired at an average cost of $3.53 per share, with a total value of $24,762.95. Following the acquisition, the chief executive officer directly owned 2,312,852 shares in the company, valued at approximately $8,164,367.56. This trade represents a 0.30% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Immuneering Trading Down 5.6%

Immuneering stock traded down $0.20 during trading on Thursday, hitting $3.39. 908,546 shares of the company were exchanged, compared to its average volume of 2,548,284. Immuneering Corporation has a 52 week low of $1.00 and a 52 week high of $3.87. The company has a market capitalization of $122.01 million, a P/E ratio of -1.73 and a beta of 0.38. The business's 50 day moving average is $1.96 and its 200 day moving average is $1.83.

Immuneering (NASDAQ:IMRX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.01). Equities analysts expect that Immuneering Corporation will post -1.86 EPS for the current year.

Institutional Trading of Immuneering

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Southport Management L.L.C. raised its stake in shares of Immuneering by 4.9% during the fourth quarter. Southport Management L.L.C. now owns 215,000 shares of the company's stock valued at $473,000 after acquiring an additional 10,000 shares during the last quarter. Rockefeller Capital Management L.P. bought a new position in shares of Immuneering during the fourth quarter valued at approximately $390,000. HighTower Advisors LLC grew its holdings in shares of Immuneering by 17.7% during the first quarter. HighTower Advisors LLC now owns 83,960 shares of the company's stock valued at $128,000 after buying an additional 12,600 shares during the last quarter. Bridgeway Capital Management LLC grew its holdings in shares of Immuneering by 77.4% during the fourth quarter. Bridgeway Capital Management LLC now owns 51,349 shares of the company's stock valued at $113,000 after buying an additional 22,400 shares during the last quarter. Finally, Two Sigma Investments LP grew its holdings in shares of Immuneering by 25.0% during the fourth quarter. Two Sigma Investments LP now owns 50,557 shares of the company's stock valued at $111,000 after buying an additional 10,126 shares during the last quarter. Hedge funds and other institutional investors own 67.65% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on IMRX shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $9.00 price objective on shares of Immuneering in a research report on Wednesday, June 18th. Mizuho boosted their price objective on shares of Immuneering from $8.00 to $10.00 and gave the stock an "outperform" rating in a research note on Wednesday, June 18th. Oppenheimer lowered their price objective on shares of Immuneering from $25.00 to $21.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Finally, Chardan Capital restated a "buy" rating and set a $13.00 target price on shares of Immuneering in a research report on Wednesday, June 18th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat.com, Immuneering has a consensus rating of "Moderate Buy" and a consensus price target of $13.25.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.